Publications by authors named "Melinda Laine Hsu"
Cancer Manag Res
November 2022
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are now standard treatment for advanced non-small cell lung cancer (aNSCLC) patients with high PD-L1 expression (≥50%) and can be given with or without chemotherapy.
- A study of 2,631 patients between 2018 and 2021 found that those receiving ICIs with chemotherapy generally had better overall survival compared to those on ICI monotherapy, especially in patients with lower PD-L1 levels (50-69%).
- The research indicates that patients in a more controlled, clinical trial-like setting had outcomes similar to those in major clinical trials, highlighting the effectiveness of ICI therapy in real-world scenarios.
